

March 27, 2026

News Release

Company: Olympus Corporation  
Bob White, Director, Representative Executive Officer, President and CEO  
(Code: 7733, Prime, Tokyo Stock Exchange)  
Contact: Takaaki Sakurai, Vice President, Investor Relations  
TEL: +81-42-642-2111

### Notification for the Candidates for the Board of Directors

Pursuant to today's resolution of the Nominating Committee, Olympus Corporation ("Olympus") announces the proposed change to the members of the Board of Directors as set out below. The appointment of Directors is subject to approval at the General Meeting of Shareholders scheduled to be held in June 2026.

#### 1. Changes in the Board of Directors

##### (1) New Director Candidate

Outside Director	Jean-Luc Butel
Outside Director	Costa Saroukos

##### (2) Departing Director

Director, Representative Executive Officer	Yasuo Takeuchi
Director	Toshihiko Okubo

#### 2. Profile of Candidate for New Director

Jean-Luc Butel

Date of Birth:	November 8, 1956	
Career summary:	Jan 1998	Corporate Officer, President, Worldwide Consumer Healthcare, Becton, Dickinson and Company
	Nov 1999	President, Independence Technology, Johnson & Johnson
	Aug 2003	President, Medtronic Asia Pacific Headquarters
	May 2008	Corporate Officer, Executive Committee Member, Executive Vice President and Group President, International, Medtronic Inc. (currently Medtronic, plc)
	Jan 2012	President, International, Baxter International Inc.
	Jul 2015	Global Healthcare Advisor, President, K8 Global Pte. Ltd. (present)
	Jun 2016	Outside Director, Takeda Pharmaceutical Company Limited (present)

	Sep 2017	Outside Director, Novo Holdings A/S
	Sep 2021	Outside Director, Rani Therapeutics (present)
	Apr 2022	Outside Director, ICOV Group (present)
Number of shares of the Company held:	0 shares	
Reason for the candidate:	<p>Mr. Jean-Luc Butel possesses extensive global knowledge and a proven track record as a business leader within several leading multinational corporations in the healthcare industry. Furthermore, he brings significant experience and objectivity gained through his service as an outside director for various global enterprises.</p> <p>Olympus Corporation has determined that Mr. Butel's high level of insight, specialized expertise, and management capabilities will contribute significantly to several key strategic areas. These attributes will strengthen governance by enhancing the board's monitoring and decision-making functions through an independent, international lens. Furthermore, his expertise will support sustainable growth by providing the strategic guidance necessary to ensure the Olympus Group's long-term expansion in the global MedTech market. Finally, Mr. Butel will play a vital role in maximizing corporate value by driving initiatives that enhance shareholder value over the medium to long term. From the above, Olympus Corporation has nominated him as a new candidate for Outside Director.</p>	

Costa Saroukos

Date of Birth:	April 15, 1971	
Career summary:	Jul 2012	Executive Finance Director EEMEA, Merck & Co.
	Oct 2013	Executive Finance Director Greater China & Japan, Allergan Asia Limited
	Sep 2014	Vice President Finance and Business Development Asia Pacific (Including China & Japan), Allergan Asia Limited
	May 2015	Chief Financial Officer of the Europe and Canada Business Unit, Takeda Pharmaceutical Company Limited
	Apr 2018	Global Chief Financial Officer, Takeda Pharmaceutical Company Limited
	Jun 2019	Director, Takeda Pharmaceutical Company Limited

	Sep 2025	Chairperson, Director of the Board, Mitsubishi Tanabe Pharma Corporation (currently Tanabe Pharma Corporation) (present)
	Dec 2025	Independent Non-Executive Director, CSL Limited (present)
Number of shares of the Company held:	0 shares	
Reason for the candidate:	<p>Mr. Costa Saroukos has global and highly specialized expertise cultivated through his extensive experience as Chief Financial Officer at several global companies in the healthcare industry, as well as through his extensive background as a Certified Practising Accountant in Australia and his experience serving as a director at another company.</p> <p>Olympus Corporation has determined that he possesses a high level of insight, expertise and capabilities, and that he will contribute to strengthening the monitoring and decision-making functions of the Board of Directors. His appointment is also expected to contribute to the sustainable growth of the Olympus Group and the long-term enhancement of corporate value. From the above, Olympus Corporation has nominated him as a new candidate for Outside Director.</p>	

(Note) “Number of shares of the Company held” indicates the number of shares held as of September 30, 2025.

3. Candidates for Directors (Subject to approval at the General Meeting of Shareholders)

Outside Director	Masato Iwasaki	Reappointment
Outside Director	David Robert Hale	Reappointment
Outside Director	Jimmy C. Beasley	Reappointment
Outside Director	Sachiko Ichikawa	Reappointment
Outside Director	Kohei Kan	Reappointment
Outside Director	Gary John Pruden	Reappointment
Outside Director	Luann Marie Penty	Reappointment
Outside Director	Hiroshi Ishino	Reappointment
Outside Director	Jean-Luc Butel	New Appointment
Outside Director	Costa Saroukos	New Appointment
Director, Representative Executive Officer	Bob White	Reappointment

(Note) Costa Saroukos is used in business, but his legal name is Constantine Saroukos.